Correction to: British Journal of Cancer (2019) 121, 611–621; 10.1038/s41416-019-0556-9, published online 4 September 2019
Since the publication of this paper, the authors have realised that the identification of the Smad2/3 antibody used was incorrect in Supplementary Table 1. The corrected identification of the Smad2/3 antibody is Cell Signaling Technologies, 8685 (D7G7). Supplementary Table 1 has been corrected accordingly. The authors would like to apologise for this error which does not alter the conclusions of the paper.